Akintunde Bello

2.4k total citations
71 papers, 1.7k citations indexed

About

Akintunde Bello is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Akintunde Bello has authored 71 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Akintunde Bello's work include Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (10 papers) and CAR-T cell therapy research (10 papers). Akintunde Bello is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (10 papers) and CAR-T cell therapy research (10 papers). Akintunde Bello collaborates with scholars based in United States, Germany and Sweden. Akintunde Bello's co-authors include Amit Roy, Xiaochen Zhao, Sachin Agrawal, Weiwei Tan, Manish Gupta, Jennifer Sheng, Hariharan Subramanian, Bridget Martell, Matthew Hruska and Brian J. Schmidt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Akintunde Bello

66 papers receiving 1.7k citations

Peers

Countries citing papers authored by Akintunde Bello

Since Specialization

Citations

This map shows the geographic impact of Akintunde Bello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akintunde Bello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akintunde Bello more than expected).

Fields of papers citing papers by Akintunde Bello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akintunde Bello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akintunde Bello. The network helps show where Akintunde Bello may publish in the future.

Co-authorship network of co-authors of Akintunde Bello

This figure shows the co-authorship network connecting the top 25 collaborators of Akintunde Bello. A scholar is included among the top collaborators of Akintunde Bello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akintunde Bello. Akintunde Bello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors 2024 ·Clinical Cancer Research ·Yue Zhao, (unknown), Sai Praneeth Bathena, (unknown), (unknown), Paul Statkevich, Akintunde Bello, Amit Roy, Satyendra Suryawanshi	7
2	Knowledge of Ocular prosthesis among students of Optical Dispensary Technology, Birnin Kebbi, Nigeria 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Akintunde Bello	0
3	Heterogeneity of ER, PgR, HER2 and Ki67 in multifocal/multicentric breast cancer with a single histotype and same grade: implications for pathologists and oncologists from a large multi-institutional series 2024 ·European Journal of Cancer ·Cristian Scatena, (unknown), Anna Maria Cremonini, Akintunde Bello, Lara Alessandrini, Enrico Orvieto, Elham Sajjadi, Bruna Cerbelli, Virginia Mancini, Carlo Riccardo Rossi, Massimo Pedriali, Patrizia Querzoli, Alberto Ravarino, Antonino Giulio Giannone, Giovanni Tuccari, (unknown), Vania Vezzosi, Maria Pia Foschini, Benedetta Bendinelli, Antonio Giuseppe Naccarato	0
4	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials 2022 ·Journal for ImmunoTherapy of Cancer ·Yoon‐Koo Kang, Martin Reck, Paul Nghiem, Feng Yan, Gregory E. Plautz, Hye Ryun Kim, Taofeek K. Owonikoko, Narikazu Boku, Li‐Tzong Chen, Ming Lei, Han Chang, Wen Lin, Amit Roy, Akintunde Bello, Jennifer Sheng	10
5	Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants 2022 ·Clinical Pharmacokinetics ·Vidya Perera, (unknown), Danshi Li, Zhaoqing Wang, Liping Zhang, (unknown), Wei Chen, Akintunde Bello, Bindu Murthy	25
6	SINGLE-DOSE PHARMACOKINETICS OF BMS-986177/JNJ-70033093 (BMS-177/JNJ-3093) IN PARTICIPANTS WITH NORMAL RENAL FUNCTION AND PARTICIPANTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT 2021 ·Journal of the American College of Cardiology ·Vidya Perera, (unknown), Danshi Li, Zhaoqing Wang, Ping Zhang, (unknown), Akintunde Bello, Bindu Murthy	1
7	Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer 2018 ·Annals of Oncology ·Georgina V. Long, Scott S. Tykodi, Jeffrey Schneider, Claus Garbe, Gwénaëlle Gravis, Michelle Rashford, Sachin Agrawal, E. Grigoryeva, Akintunde Bello, A. Roy, Lætitia Rollin, Xiaochen Zhao	122
8	Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer 2017 ·Clinical Cancer Research ·Feng Yan, Xiaoning Wang, Gaurav Bajaj, Shruti Agrawal, Akintunde Bello, Brian Lestini, Friedrich Graf Finckenstein, Jong-Soon Park, Amit Roy	82
9	An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab 2017 ·The AAPS Journal ·Chaitali Passey, Johanna Mora, Robert Dodge, Leonid Gibiansky, Jennifer Sheng, Amit Roy, Akintunde Bello, Manish Gupta	9
10	Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors 2017 ·Annals of Oncology ·Xiaochen Zhao, Satyendra Suryawanshi, Matthew Hruska, Yufei Feng, (unknown), Jun Shen, Heather Vezina, M. Brent McHenry, Ian M. Waxman, (unknown), Akintunde Bello, Amit Roy, Sachin Agrawal	142
11	Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non–Small Cell Lung Cancer 2016 ·Clinical Cancer Research ·Erjian Wang, Dana J. Nickens, Akintunde Bello, Reza Khosravan, Michael Amantea, Keith D. Wilner, Kourosh Parivar, Weiwei Tan	20
12	Assessment of nivolumab (Nivo) benefit-risk profile from a 240-mg flat dose versus a 3-mg/kg dosing regimen in patients (Pts) with solid tumors 2016 ·Annals of Oncology ·Xiaochen Zhao, Satyendra Suryawanshi, Matthew Hruska, Feng Yan, (unknown), Jun Shen, (unknown), Ian M. Waxman, (unknown), Akintunde Bello, Amit Roy, Sachin Agrawal	3
13	Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer 2016 ·Clinical Drug Investigation ·Weiwei Tan, Shinji Yamazaki, Theodore R. Johnson, Rong Wang, Melissa O’Gorman, (unknown), (unknown), Nicoletta Brega, Akintunde Bello	16
14	The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects 2015 ·European Journal of Clinical Pharmacology ·Huiping Xu, Melissa O’Gorman, Weiwei Tan, Nicoletta Brega, Akintunde Bello	26
15	Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects 2014 ·The Journal of Clinical Pharmacology ·Huiping Xu, Melissa O’Gorman, (unknown), Nicoletta Brega, (unknown), Weiwei Tan, Akintunde Bello	36
16	Dosing Celecoxib in Pediatric Patients With Juvenile Rheumatoid Arthritis 2011 ·The Journal of Clinical Pharmacology ·Sriram Krishnaswami, Matt Hutmacher, Jeffery Robbins, Akintunde Bello, Christine R. West, Bradley J. Bloom	10
17	Intravenous Parecoxib Rapidly Leads to COX-2 Inhibitory Concentration of Valdecoxib in the Central Nervous System 2007 ·Clinical Pharmacology & Therapeutics ·Vivek Mehta, A. E. Johnston, Raymond Cheung, Akintunde Bello, (unknown)	26
18	Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats 2004 ·Archives of Toxicology ·Michael Kästner, (unknown), (unknown), Akintunde Bello, Ralf Stahlmann	7
19	Effect of Garenoxacin on Eubacteria in the Normal Intestinal Microflora when Administered Concomitantly with Digoxin 2003 ·Journal of Chemotherapy ·C. E. Nord, Lennart Meurling, (unknown), Akintunde Bello, Dennis M. Grasela, (unknown)	2
20	Effect of a High‐Fat Meal on the Pharmacokinetics of the Des‐F(6)‐Quinolone BMS‐284756 2002 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), (unknown), Akintunde Bello, Zhiyu Ge, Lisa J. Christopher, Dennis M. Grasela	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact